Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
March 04, 2024 08:30 ET | Ascendis Pharma
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
February 07, 2024 16:01 ET | Ascendis Pharma
Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 08:30 ET | Ascendis Pharma
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
January 31, 2024 16:15 ET | Ascendis Pharma
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday,...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
January 31, 2024 16:01 ET | Ascendis Pharma
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone...
Ascendis_FINAL_LOGO_7.23.15.png
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
January 29, 2024 08:30 ET | Ascendis Pharma
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Introduces Vision 2030
January 07, 2024 17:45 ET | Ascendis Pharma
Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) --...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023 16:15 ET | Ascendis Pharma
COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice...
Ascendis_FINAL_LOGO_7.23.15.png
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
December 20, 2023 08:30 ET | Ascendis Pharma
TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20,...
Ascendis_FINAL_LOGO_7.23.15.png
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
December 19, 2023 08:30 ET | Ascendis Pharma
–   On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared...